Initial Use Experience of Durvalumab Plus Gemcitabine and Cisplatin for Advanced Biliary Tract Cancer in a Japanese Territory Center
Authors:
- Kento ShionoyaKSKento Shionoya
- Atsushi SofuniASAtsushi Sofuni
- Shuntaro MukaiSMShuntaro Mukai
- Yoshiya YamauchiYYYoshiya Yamauchi
- Takayoshi TsuchiyaTTTakayoshi Tsuchiya
- Reina TanakaRTReina Tanaka
- Ryosuke TonozukaRTRyosuke Tonozuka
- Kenjiro YamamotoKYKenjiro Yamamoto
- Kazumasa NagaiKNKazumasa Nagai
- Yukitoshi MatsunamiYMYukitoshi Matsunami
- Hiroyuki KojimaHKHiroyuki Kojima
- Hirohito MinamiHMHirohito Minami
Open Access
Abstract
Background: Biliary tract cancers (BTCs), including gallbladder and bile duct cancers, have a poor prognosis. Recent advances in chemotherapy, such as using targeted drugs for specific gene mutations, have improved outcomes. Gemcitabine plus cisplatin chemotherapy has been the standard of care for the primary treatment of BTCs, but secondary treatment had not been established until recently. In recent years, durvalumab plus gemcitabine and cisplatin (GCD) chemotherapy is emerging as a promising regimen, although more evidence is needed for its effectiveness. Methods: This retrospective single-center study involved 44 patients receiving GCD treatment between January 2023 and March 2024 with a median follow-up of 10 months. Outcomes focused on overall survival (OS), progression-free survival (PFS), response rates, and adverse events (AEs). Results: The overall response rate (ORR) was 23%, and the disease control rate (DCR) was 82%. The overall median OS and PFS were 15.3 and 8.0 months, respectively, with patients receiving primary chemotherapy experiencing longer survival compared to a control group. Patients who did not undergo bile duct drainage had statistically different better OS and PFS. Grade 3 or higher AEs occurred in 54.5% of patients, with neutropenia and biliary infections being common. Conclusions: GCD chemotherapy shows potential as an effective treatment for BTCs. The favorable treatment outcome was the response rate, particularly in primary therapy or those cases with no metastasis. Bile duct management is crucial for improving patient outcomes. GCD chemotherapy has a high response rate, PFS, and OS compared to other forms of chemotherapy.Keywords
This publication has 31 references indexed in Scilit:
- Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter StudyTargeted Oncology, 2024
- Durvalumab Plus Gemcitabine and Cisplatin in Patients with Advanced Biliary Tract Cancer: An Exploratory Analysis of Real-World DataTargeted Oncology, 2024
- Comparison of unilateral and bilateral intraductal plastic stent placement for unresectable malignant hilar biliary obstruction: A propensity score‐matched cohort analysisJournal of Hepato-Biliary-Pancreatic Sciences, 2023
- Randomized phase III study of gemcitabine, cisplatin plus S‐1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401‐ MITSUBA)Journal of Hepato-Biliary-Pancreatic Sciences, 2022
- Molecular detection and clinicopathological characteristics of advanced/recurrent biliary tract carcinomas harboring the FGFR2 rearrangements: a prospective observational study (PRELUDE Study)Journal of Gastroenterology, 2020
- A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract CancerJAMA Oncology, 2020
- Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE‐158 and KEYNOTE‐028 studiesInternational Journal of Cancer, 2020
- Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract CancersJAMA Oncology, 2019
- Prediction of drainage effectiveness during endoscopic stenting of malignant hilar strictures: the role of liver volume assessmentGastrointestinal Endoscopy, 2010
- Endoscopic biliary therapy using the combined percutaneous and endoscopic techniqueGastroenterology, 1989